Anthos Therapeutics, Inc.
Clinical trials sponsored by Anthos Therapeutics, Inc., explained in plain language.
-
Cancer clot study halted: new drug vs standard care
Disease control TerminatedThis study tested a new blood thinner called abelacimab against the standard drug apixaban in about 1,150 people with cancer who had a blood clot. The goal was to see which drug better prevented new clots and caused less bleeding. The study was stopped early, but the results may …
Phase: PHASE3 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 05:30 UTC
-
New blood thinner tested for cancer patients with dangerous clots
Disease control TerminatedThis study tested a new blood thinner called abelacimab against the standard drug dalteparin in 417 adults with stomach, bowel, or urinary cancers who also had blood clots. The goal was to see which drug better prevented new clots and caused less bleeding. The study was stopped e…
Phase: PHASE3 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC